BioMarin Pharmaceutical Inc. has bounced back from a stock price slump that occurred after it reported that pegvaliase, the company's second therapy to treat phenylketonuria (PKU), met the primary endpoint in a Phase III clinical trial, but failed to meet a key secondary endpoint.
BioMarin Pharmaceutical Inc. has bounced back from a stock price slump that occurred after it reported that pegvaliase, the company's second therapy to treat phenylketonuria (PKU), met the primary endpoint in a Phase III clinical trial, but failed to meet a key secondary endpoint.
BioMarin fell 3.4% on March 21, but jumped 6.7% to close at $83.43 per share on March 22 after investors...
Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.
The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.
The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.
